CD8A and neoplasm: Most immunotherapy strategies devote to reinvigorate T cell function to evoke effective anti-tumor immune responses (Borst et al., 2018) and most clinical settings focus on the exploiting of cytotoxic CD8+ T lymphocytes (CD8+ CTLs) (Rosenberg and Restifo, 2015; Ott et al., 2017).